Objective To explore the value of metagenomic next-generation sequencing (mNGS) in the diagnosis and treatment of severe pneumonia after renal transplantation .Methods A total of 38 patients with severe pneumonia after renal transplantation from October 2017 to December 2018 were selected and divided into experimental group (A ,n= 15)and control group (B ,n= 23) based upon whether mNGS of bronchoalveolar lavage fluid was employed for detecting pathogenic microorganisms .Positive rate ,clinical acceptance rate ,hospitalization time ,hospitalization expenses and 28-day mortality rate of two methods were compared .Results Positive rate and clinical acceptance rate of mNGS were higher in experimental group than those in traditional experimental and control groups ( P < 0 .05 ) . Hospitalization time , hospitalization expenses and 28-day mortality of experimental group were lower than those of control group (P< 0 .05) .No significant inter-group difference existed in 90-day mortality (P> 0 .05) .Conclusions For patients with severe pneumonia after renal transplantation , mNGS of bronchoalveolar lavage fluid can improve positive rate of etiological diagnosis and clinical acceptance rate and reduce hospitalization time , hospitalization expenses and 28-day mortality .

The efficacy of HPV vaccine in preventing cervical cancer has been demonstrated in numerous clinical trials and clinical uses. The follow-up after clinical trials usually last for 5-6 years to evaluate the long-term efficacy, and a series of long-term follow-up studies have been conducted in some regions. The literature retrieval of HPV vaccine long term efficiency research both at home and abroad indicated that the protective efficacy of the vaccine against vaccine-type-related cervical intraepithelial neoplasia grade 2 and above is higher than 90%.
Humans ; Human Papillomavirus Viruses ; Biomedical Research ; Papillomavirus Vaccines